Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, et al
Although these therapies reduce tumor burden and AR activity, the cancer inevitably recurs within 1830 months
Plasma exposure for oral semaglutide was shown to be dose-dependent in a multiple-dose study ( N = 84 healthy male individuals and 23 male individuals with T2D)
Implications for healthcare providers and insurers: As GLP-1 use expands, providers and payers should focus more on persistence and cost effectiveness
Yang and co-workers reported a nanomedicine composed of dendritic mesoporous silica nanoparticles (DMSNs), Fe 3 O 4 , Mn, and glutaminase inhibitor Telaglenastat (CB-839) (termed DFMC) for restored oxaliplatin chemosensitivity on the basis of the GSH-responsive and -exhausting effect (Figure 4C) (Wu et al., 2022
SeekPeptides serves as a trusted resource for evidence-based peptide information helping researchers make informed decisions about compounds, vendors, and protocols